Zimmer Biomet Holdings, Inc. (NYSE:ZBH) updated its FY17 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $8.01-$8.07 for the period, compared to the Thomson Reuters consensus estimate of $8.23. The company issued revenue guidance of $7.76-$7.80 billion, compared to the consensus revenue estimate of $7.83 billion.Zimmer Biomet Holdings also updated its Q4 guidance to $2.08-$2.14 EPS.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same quarter in the prior year, the firm earned $1.79 EPS. The business’s quarterly revenue was down .8% compared to the same quarter last year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Shareholders of record on Friday, September 22nd were issued a $0.24 dividend. The ex-dividend date was Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.
A number of equities analysts have commented on ZBH shares. BMO Capital Markets reiterated a buy rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Guggenheim raised shares of Zimmer Biomet Holdings from a neutral rating to a buy rating and set a $157.00 target price for the company in a research report on Wednesday, July 12th. Needham & Company LLC reissued a strong-buy rating and issued a $153.00 target price on shares of Zimmer Biomet Holdings in a research report on Wednesday, July 12th. Canaccord Genuity reissued a buy rating and issued a $141.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Finally, Royal Bank Of Canada reissued an outperform rating and issued a $140.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $136.55.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/11/02/zimmer-biomet-holdings-inc-zbh-releases-fy17-earnings-guidance.html.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.